DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

Publisher： Karger

E-ISSN： 1423-0143|36|1|119-130

ISSN： 1420-4096

Source： Kidney and Blood Pressure Research, Vol.36, Iss.1, 2012-10, pp. : 119-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Therapies for Diabetic Nephropathy Patients: Beyond Blockade of the Renin-Angiotensin System

By  

Nephron Extra, Vol. 2, Iss. 1, 2012-10 ,pp. : 278-282

Karger

Access to resources Recommend Favorite

Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy

By  

American Journal of Nephrology, Vol. 19, Iss. 1, 1999-03 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy

By  

Kidney and Blood Pressure Research, Vol. 33, Iss. 3, 2010-06 ,pp. : 213-220

Karger

Access to resources Recommend Favorite

Beneficial Effect of Combination Therapy with an Angiotensin II Receptor Antagonist and Angiotensin-Converting Enzyme Inhibitor on Overt Proteinuria in a Patient with Type 1 Diabetic Nephropathy

By  

Nephron, Vol. 86, Iss. 4, 2000-12 ,pp. : 529-530

Karger

Access to resources Recommend Favorite

Comparison between the Angiotensin II Receptor Antagonist Candesartan Cilexetil and the Angiotensin-Converting Enzyme Inhibitor Trandolapril in Microalbuminuria of Patients with Early Diabetic Nephropathy

By  

Nephron, Vol. 86, Iss. 2, 2000-09 ,pp. : 247-247

Karger

Access to resources Recommend Favorite